Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27671172 | 0.76 | CYP17A1 (0.47) | L3MBTL1NR1H4 | |
| SCHEMBL27081744 | 0.76 | HPGD (0.44) | TSHRTP53HSD17B10HTTSMN1; SMN2 | |
| SCHEMBL27971471 | 0.74 | PIK3CA (0.45) | TSHREPHX1TP53GAAL3MBTL1 | |
| SCHEMBL12471517 | 0.74 | — | — | |
| SCHEMBL3299936 | 0.73 | — | — | |
| SCHEMBL2706420 | 0.69 | HPGD (0.42) | TSHRTP53GAAL3MBTL1HTT | |
| SCHEMBL4986967 | 0.69 | SMN1; SMN2 (0.36) | TSHRHSD17B10GAAL3MBTL1PKM | |
| SCHEMBL7498207 | 0.69 | KMT2A (0.36) | TSHRGAAL3MBTL1HTTALDH1A1 | |
| SCHEMBL3550831 | 0.69 | KDM4E (0.43) | TSHRHSD17B10GAAHTTSMN1; SMN2 | |
| SCHEMBL3818645 | 0.69 | PRKCI (0.36) | GAAKDM4EALDH1A1TDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | claimed |
| CN-103517710-A | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC | 2014-01-15 | — | — | CN | claimed |
| EP-2672967-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2013-12-18 | — | — | EP | claimed |
| WO-2012109075-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2012-08-16 | — | — | WO | claimed |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2022-05-24 | — | — | US | disclosed |
| EP-2672967-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20170157120-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-9624213-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
| CN-103517710-A | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC | 2014-01-15 | — | — | CN | disclosed |
| EP-2672967-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| US-20120022044-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2012-01-26 | — | — | US | disclosed |
| EP-2378879-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Corp. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010071741-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2010-06-24 | — | — | WO | disclosed |
| US-7122565-B2 | Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT LLC (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1326853-B1 | THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | WARNER LAMBERT CO (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1326853-A1 | NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | Warner-Lambert Company LLC (US) | 2003-07-16 | — | — | EP | disclosed |
| US-20030045557-A1 | Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors | WARNER-LAMBERT COMPANY | 2003-03-06 | — | — | US | disclosed |
| WO-2002028847-A1 | NEW THIADIAZOLES AND OXADIAZOLES AND THEIR USE AS PHOSPHODIESTERASE-7 INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2002-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022044-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MAPT, BACE1, APP | TSHR 1748/4885EPHX1 1531/4885TP53 1456/4885 |
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K20, PRKACA, MAP3K13 | TSHR 3588/4885EPHX1 3230/4885TP53 576/4885 |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | TSHR 3588/4885EPHX1 3230/4885TP53 576/4885 |
| US-20140128373-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | TSHR 3588/4885EPHX1 3230/4885TP53 576/4885 |
| US-20030045557-A1 | Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors | PDE3A, PDE3B, PDE7A | TSHR 1168/4885EPHX1 1021/4885TP53 4799/4885 |
| US-20170157120-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | TSHR 3588/4885EPHX1 3230/4885TP53 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.